These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28786125)

  • 1. Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.
    McBrayer DN; Tal-Gan Y
    Drug Dev Res; 2017 Sep; 78(6):292-299. PubMed ID: 28786125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.
    Swedberg JE; Schroeder CI; Mitchell JM; Durek T; Fairlie DP; Edmonds DJ; Griffith DA; Ruggeri RB; Derksen DR; Loria PM; Liras S; Price DA; Craik DJ
    Eur J Med Chem; 2015 Oct; 103():175-84. PubMed ID: 26352676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A; Knop FK; Vilsbøll T
    Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential.
    Han J; Chen X; Wang Y; Fei Y; Zhou F; Zhang Y; Liu L; Si P; Fu J
    Biochem Pharmacol; 2017 Oct; 142():155-167. PubMed ID: 28668697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GLP-1 analogues in treatment of type 1 diabetes mellitus].
    Tölle S
    Dtsch Med Wochenschr; 2014 Oct; 139(42):2123-6. PubMed ID: 25289919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 peptide analogs for targeting pancreatic beta cells.
    Alavi SE; Ebrahimi Shahmabadi H
    Drug Discov Today; 2021 Aug; 26(8):1936-1943. PubMed ID: 33839290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists.
    Fang H; Niu B; Chen Q
    Curr Med Chem; 2024; 31(20):2921-2943. PubMed ID: 37062063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
    Ross SA; Ballantine J
    Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
    Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
    Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor.
    Bird GH; Fu A; Escudero S; Godes M; Opoku-Nsiah K; Wales TE; Cameron MD; Engen JR; Danial NN; Walensky LD
    ACS Chem Biol; 2020 Jun; 15(6):1340-1348. PubMed ID: 32348108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists.
    Icart LP; Souza FG; Lima LMTR
    J Microencapsul; 2021 Jun; 38(4):249-261. PubMed ID: 33586588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.